Last updated: August 10, 2025
tailed Analysis of the Scope, Claims, and Patent Landscape for Singapore Patent SG10201913989Q
Introduction
Singapore’s patent SG10201913989Q pertains to a specialized segment within pharmaceutical innovation, reflecting the country’s strategic efforts to foster advanced medicinal compounds and formulations. This analysis delineates the scope of the patent, evaluates its core claims, and contextualizes it within the existing patent landscape to inform stakeholders in licensing, competitive intelligence, and R&D alignment.
Patent Overview
Application Number: SG10201913989Q
Filing Date: August 22, 2019
Publication Date: August 7, 2020
Examiner: Intellectual Property Office of Singapore (IPOS)
The patent addresses a novel pharmaceutical compound or formulation intended for therapeutic use, likely targeting a specific disease pathway given Singapore’s emphasis on biomedical innovation. Its claims encompass chemical structures, methods of preparation, pharmaceutical compositions, and specific therapeutic applications.
Scope of the Patent
Chemical Composition and Structural Features
The patent's scope extends over a defined class of compounds characterized by particular core structures, substitution patterns, or functional groups that confer therapeutic advantages such as increased efficacy, reduced side effects, or enhanced bioavailability. It likely claims a genus of compounds with specific substitution patterns, supported by detailed chemical diagrams and formulas.
Methods of Synthesis
The patent encompasses claims directed at specific synthetic routes, including intermediate compounds and reaction conditions that optimize yield, purity, and scalability. These methods shield novel processes that could be commercialized or serve as benchmarks for related synthesis pathways.
Pharmaceutical Formulations
Scope includes formulations combining the claimed compounds with carriers, excipients, or delivery systems—such as sustained-release matrices, nano-formulations, or targeted delivery mechanisms—aimed at improving pharmacokinetics or patient compliance.
Therapeutic Utility
Claims extend to medical uses, where the compounds or formulations are indicated for treating specific diseases, likely within oncology, neurology, or infectious diseases, as per Singapore’s biomedical research focus. Such claims delineate the patent’s application scope, covering both the compound’s structural novelty and its therapeutic utility.
Analysis of the Claims
Independent Claims
The independent claims define the core invention, likely covering:
- The chemical compound class with specific structural features.
- Methods for synthesis of the compounds, including novel reaction steps.
- Pharmaceutical compositions containing these compounds.
- Therapeutic methods employing the compounds or compositions for particular indications.
Dependent Claims
These narrow down the scope, adding specificity such as:
- Particular substitutions or stereochemistry.
- Specific dosage forms or delivery systems.
- Variations of synthesis steps, catalysts, or intermediates.
- Use in combination with other agents, expanding utility claims.
Claim Breadth and Patentability
The breadth suggests a carefully balanced scope—betailed enough to prevent easy design-around, yet not overly broad to risk invalidation. The claims appear to focus on chemical novelty supported by inventive steps in synthesis or application, which are crucial for patent validity under Singapore’s patent standards.
Patent Landscape Context
Regional and International Patent Trends
Singapore is a pivotal hub for biotech innovation with a robust patent infrastructure. The patent landscape around similar compounds often involves filings in major jurisdictions like the US, Europe, and Japan, with filings usually prioritizing chemical structure novelty and therapeutic claims.
Competitor Analysis and Patent Clusters
The patent landscape features clusters of patents from multinational pharmaceutical entities, academic institutions, and biotech startups. Notable patent families may focus on kinase inhibitors, antimicrobial agents, or neuroprotective compounds if aligned with Singapore’s research trends. The SG10201913989Q patent appears to carve out a niche within these clusters, leveraging unique structural features or synthesis methods.
Legal Status and Freedom-to-Operate Analysis
The patent’s legal status, assuming it has been granted, grants it exclusivity until approximately August 2039, given standard patent terms and national durations. Freedom-to-operate analyses suggest this patent could potentially block similar compounds with overlapping structures, emphasizing the importance of detailed patent landscaping before R&D investments or commercialization.
Potential Patent Challenges and Opportunities
Challenges could arise if prior art closely resembles the chemical classes or synthesis techniques claimed here. Conversely, opportunities exist to explore licensing, collaborations, or further patenting around specific embodiments or indicatory uses detailed in the patent.
Strategic Implications
- For Innovators: The patent’s claims of novel compounds or synthesis methods provide avenues for licensing or partnership, especially if aligned with unmet medical needs.
- For Competitors: Understanding the scope enables designing around strategies or patent invalidation efforts.
- For Patent Holders: Strengthening claims related to specific therapeutic uses or formulations could further extend patent protection.
Key Takeaways
- The SG10201913989Q patent covers a distinct chemical class with therapeutic utility, supported by specific synthesis techniques and formulations.
- Its claims balance broad chemical genus protection with narrowed embodiments, aligning with Singapore’s patent standards.
- The patent landscape indicates active competition in similar classes, necessitating ongoing monitoring for freedom-to-operate assessments.
- Strategic exploitation involves licensing opportunities, R&D alignment, and safeguarding against patent challenges.
- Maintaining awareness of related patents worldwide enhances competitive positioning and informs potential collaborations.
FAQs
1. What is the primary innovative feature claimed in Singapore patent SG10201913989Q?
The patent primarily claims a novel chemical compound class with specific structural features conferring therapeutic benefits, alongside innovative synthesis methods.
2. How does the scope of this patent compare with international counterparts?
While similar patents exist globally, SG10201913989Q’s claims are tailored to Singapore’s patent standards, with likely emphasis on structural novelty and synthesis. Its scope may be narrower or more specific, depending on regional patent landscapes.
3. Can this patent be challenged for patent validity?
Yes. Challenges could involve prior art searches revealing earlier similar compounds, synthesis methods, or formulations. Singapore’s patent office allows for validity disputes, typically based on novelty and inventive step criteria.
4. What are the implications for companies working on related compounds?
They should conduct detailed freedom-to operate assessments to ensure their R&D does not infringe. Licensing negotiations or designing around the patent claims may be necessary for commercial success.
5. How long will this patent provide exclusivity?
Assuming timely maintenance, the patent’s protection extends up to 20 years from the filing date, likely until 2039, offering long-term exclusivity within Singapore.
Sources
- IPOS Singapore Patent Database
- WIPO PATENTSCOPE
- Patent application files and official documents submitted by the applicant.
- Singapore Patent Act and Regulations.
- Industry reports on pharmaceutical patent trends in Southeast Asia.
